Summary

In adults with heart failure and preserved ejection fraction, the mineralocorticoid receptor antagonist spironolactone did not significantly reduce the composite primary outcome of cardiovascular mortality, aborted cardiac arrest, or hospitalization for heart failure (HF) compared with placebo, but it did reduce HF hospitalizations. This article presents the results of the Treatment of Preserved Cardiac Function With an Aldosterone Antagonist [TOPCAT; NCT00094302] study.